The global TB vaccine treatment market is expected to grow at a significant CAGR during the forecast period (2021-2027).  As per the World Health Organization (WHO), in 2020, an estimated 10 million people fell ill with tuberculosis (TB) globally, which includes 5.6 million men, 3.3 million women and 1.1 million children. Globally, the number of patients receiving TB prevention treatment climbed from 1 million in 2015 to 3.6 million in 2019. Government measures and international support to reduce tuberculosis prevalence is contributing to the growth of the global TB vaccine treatment market. As per the World Health Organization (WHO) global tuberculosis (TB) report 2021, in August 2021, there were 25 drugs in Phase I, Phase II, or Phase III trials for the treatment of drug-susceptible TB, MDR-TB, or TB infection. 

There are 16 new chemical entities, two accelerated regulatory approval medications, one drug recently approved by the US Food and Drug Administration under the limited population pathway for antibacterial and antifungal treatments, and six repurposed drugs among these drugs. Several combination regimens involving new or repurposed drugs, as well as host-directed therapy, are now in Phase II or Phase III trials. There were 14 vaccine candidates in clinical trials as of August 2021, with two in Phase I, eight in Phase II, and four in Phase III. The bacille Calmette-Guérin (BCG) vaccine is the only approved vaccination for TB prevention. The BCG vaccine, which was created about a century ago and is routinely used, prevent severe types of TB in children. Although results from a Phase II trial of the M72/AS01E candidate are promising, there is presently no vaccination that is effective in preventing TB disease in adults, either before or after exposure to TB infection.

To tackle TB, India has developed the National Strategic Plan (NSP) for TB Elimination 2017-2025, which accounts for half a million global TB mortality. India also established the India TB Research Consortium to promote the development of TB vaccines and medications. A considerable percentage of TB patients are seen in developed locations such as North America. According to the Centers for Disease Control and Prevention, 9,093 cases of TB were reported in the US in 2017. Each patient's treatment costs for MDR-TB and XDR-TB were around $160,000 and $513,000, respectively. This in turn, is driving the demand for TB vaccines in the country.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Merck & Co., Inc., Sanofi SA, and GlaxoSmithKline plc, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global TB Vaccine Treatment Market Report by Segment

By Product 

• Immune Vaccine
• Therapy Vaccine

Global TB Vaccine Treatment Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa